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ABSTRACT  
Adenosine is a critical regulator of inflammation and fibrosis, it affects endogenous cell signaling via binding to 
the A3 adenosine receptor. FM101 is a potent, highly selective A3 adenosine receptor modulator that has been 
developed as a treatment for glaucoma and hepatitis. We determined that FM101 is a biased ligand with functional 
activities both as a G protein agonist and a β-arrestin antagonist. The safety of FM101 was evaluated by adminis-
tering an acute dose in rats, the results indicated that the approximate lethal dose was greater than 2000 mg/kg. In 
a subchronic toxicity study, FM101 was administered orally once per day to rats at doses of 250, 500, and 1000 
mg/kg/day over a period of 28 days. Abnormal posture, irregular respiration, decreased movement, and ear flush-
ing were observed during the early phase of dosing, and loose stools were observed sporadically among the animals 
that received 500 and 1000 mg/kg/day. Body weight and food consumption were decreased in one male and one 
female rat in the 1000 mg/kg/day group during the first 2 weeks of observation. However, there were no test 
substance-related changes or adverse effects observed during our ophthalmological, clinical chemistry, urine, or-
gan weight, and histopathological analysis. These findings indicate that no observed adverse effect level of FM101 
was 1000 mg/kg/day in male and female rats. 
 
Keywords: Adenosine, A3AR modulator, acute oral toxicity, 28-day subchronic toxicity 
 
 
 
INTRODUCTION 
Adenosine has a nucleotide-based struc-
ture and it regulates regulating endogenous 
cell signaling via binding to adenosine recep-
tor (AR) subtypes A1, A2A, A2B, and A3. 
Among ARs, A3AR is a well-known G pro-
tein-coupled receptor (GPCR) that is ex-
pressed abundantly on inflammatory tissues, 
and its selective compounds are effective for 
the treatment of inflammation or fibrosis 
(Cronstein and Sitkovsky, 2017; Borea et al., 
2018; Lee et al., 2013; Yu et al., 2019). Aden-
osine agonists or antagonists, when used in 
pharmacological studies, have been shown to 
be effective for lowering intraocular pressure 
(IOP) depending on the AR subtype 
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(Jacobson and Civan, 2016; Lu et al., 2017; Li 
et al., 2018). Among the various adenosine re-
ceptors, the A3AR could be a promising target 
to reduce elevated IOP since IOP reduction 
has been achieved through selective A3AR 
agonists and antagonists demonstrated in var-
ious animals (Yang et al., 2005; Okamura et 
al., 2004). The most promising A3AR full ag-
onists, such as IB-MECA and Cl-IB-MECA, 
have shown a good safety profile in patients 
during clinical trials and nonclinical safety 
studies (Stemmer et al., 2013; Jacobson et al., 
2019). 
FM101 is a chemically synthesized novel 
A3 adenosine receptor modulator. It is de-
scribed as a truncated analog of D- or L-4′-
thionucleoside (Jeong et al., 2008), and has 
the following full nomenclature: 
[(2R,3R,4S)-2-[2-chloro-6-(3-chlorobenzyla-
mino)-9H purine-9-yl]-tetrahydrothiophene-
3,4-diol]. FM101 was synthesized based on 
the D-4'-thioadenosine derivatives without a 
4'-hydroxymethyl group; its synthesis begins 
with D-mannose and has key steps consisting 
of cyclization to the 4-thiosugar and a one-
step conversion of the diol to the acetate. This 
novel N6-substituted analog binds to the hu-
man A3AR with high potency, selectivity, and 
binding affinity. It is being developed as a 
therapeutic for high IOP in cases of glaucoma 
and to decrease for inflammation and fibrosis 
in non-alcoholic steatohepatitis and kidney 
disease (Lee et al., 2013; Shon et al., 2019; 
Lee et al., 2017).  
There have been several investigations 
evaluating the efficacy or tolerability of can-
didates targeting A3AR in mice that overex-
press or lack these receptors (Black et al., 
2002; Harrison et al., 2002; Xiao et al., 2019). 
However, there is very few published studies 
reporting the non-clinical toxicity of agents 
that are highly selective for the A3AR and/or 
have biased functional activity on the A3AR. 
Thus, this study aimed to assess the safety 
profile of FM101 in nonclinical toxicity stud-
ies.  
 
MATERIALS AND METHODS 
FM101: production and characteristics 
FM101 was supplied by Futuremedicine 
Co., Ltd. (Republic of Korea) as an off-white 
powder with a purity >99.0 %. It was stored 
at 4 °C in a sealed container with silica gel. 
 
cAMP accumulation and β-arrestin  
translocation assays 
A cAMP accumulation assay was con-
ducted using Euroscreen FAST in accordance 
with the service supplier’s instructions. CHO-
K1 cells expressing human A3AR were mixed 
with forskolin and increasing concentrations 
of FM101. After incubating the cells with ly-
sis buffer, cAMP concentrations were esti-
mated using a homogeneous time-resolved 
fluorescence (HTRF) assay kit (Perkin Elmer, 
USA). 
The translocation of β-arrestin was evalu-
ated using a PathHunter™ β-arrestin assay kit 
(Fremont, USA) from DiscoverX according 
to previously described procedures (Alnouri 
et al., 2015; Olson and Eglen, 2007). To eval-
uate the antagonist function of FM101, CHO-
K1 cells expressing human A3AR were pre-
incubated at ten concentrations ranging from 
0.05 nM to 1 μM with a three-fold increase of 
concentration of FM101, followed by treat-
ment with 0.06 μM of 2‐Cl‐IB‐MECA as a 
reference agonist. After incubation with the 
assay buffer, a chemiluminescent the assay 
signal was generated using a commercial 
PathHunter Detection reagent cocktail. 
 
Experimental animals and test system 
For the acute toxicity study, male and fe-
male Sprague-Dawley (SD) rats (Crl:CD 
SPF) rats were purchased from Orient Bio Inc 
(Seungnam, Republic of Korea). For the sub-
chronic exposure study over 28 days, male 
and female SD rats were acquired from 
Charles River Laboratories Inc. (Japan). Ro-
dent pellet feed (Envigo RMS, Inc., U.S.A. or 
Oriental Yeast Co., Ltd. Japan) and sterile tap 
water were provided ad libitum during the ex-
periment. Rats were housed in stainless steel 
cages at appropriate temperature (21–25 °C) 
and relative humidity (40–70 %). Animal 
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housing facilities maintained under an auto-
matic 12-h light/dark light cycle. Animals 
were allowed to acclimatize to the housing 
conditions at least 1 week prior to the experi-
ments. Animal husbandry procedures fol-
lowed the recommendations of the Associa-
tion for Assessment and Accreditation of La-
boratory Animal Care International. All acute 
and subacute studies were approved by the 
IACUC of Biotoxtech Co., Ltd and INA Re-
search Inc., respectively (IACUC Accredited 
No. 160580 for acute toxicity; Accredited No. 
001107 for subacute toxicity). 
 
Acute oral dose toxicity study 
The acute single oral dose toxicity of 
FM101 was investigated by Biotoxtech Co. 
Ltd., Republic of Korea, in accordance with 
good laboratory procedures (GLP). Five male 
and five female rats were dosed orally with 
FM101 in a 0.5 % methylcellulose (MC) so-
lution at a dose of 2,000 mg/kg with a dose 
volume of 10 mL/kg. A group of control ani-
mals was dosed with the MC solution (vehi-
cle) only. All animals were observed at least 
once at 0.5, 1, 2, 4, and 6 h after treatment and 
once daily thereafter for 14 days. Body 
weights were recorded on the day of treatment 
(Day 0) and again on Days 1, 3, 7, and 14. Af-
ter the observation period, the rats were eu-
thanized and complete gross postmortem 
evaluations were conducted. 
 
Subchronic oral dose toxicity study 
Subchronic toxicity was investigated at 
Ina Research Inc., Japan, in accordance with 
the GLP standards for non-clinical safety 
studies. During a 4-week repeated dose tox-
icity study, FM101 in 0.5 % MC solution (ve-
hicle) was administered via gastric intubation 
once daily at a dose volume of 10 mL/kg. The 
rats were divided into four groups containing 
ten male and ten female rats each; three 
groups received 250, 500, and 1000 
mg/kg/day as the low-, mid-, and high-dose 
groups, respectively; the control group, com-
prising ten male and ten female rats received 
vehicle only. Six male and six female rats in 
the control and high-dose groups were allo-
cated for recovery studies with the post-expo-
sure effects assessed over a 2-week period af-
ter dosing ceased. All animals were observed 
twice a day for clinical signs and mortality. 
Body weights were recorded on the first dos-
ing day (Day 1) and once a week thereafter 
during the study period. Total food consump-
tion was recorded, and mean daily consump-
tion was calculated. Ophthalmological exam-
ination was conducted in both eyes prior to 
dosing, during week 4 of dosing, and during 
week 2 of the recovery period after topical ap-
plication of mydriatic agents on the eyes. The 
anterior portions of the eyes, including the op-
tic media and fundi, were observed and eval-
uated using a slit lamp or a binocular indirect 
ophthalmoscope. Blood, serum, and urine 
samples were collected and analyzed during 
the week 4 of dosing and week 2 of recovery. 
At the end of the experimental period, the 
animals were euthanized under isoflurane an-
esthesia. Absolute organ weights were rec-
orded and organ to terminal body weight ra-
tios (relative organ weights) were calculated 
based on the body weight at the time of nec-
ropsy. For histopathological examination, the 
obtained organs and tissues were preserved in 
10 % neutral buffered formalin. The testes 
and eyes with the optic nerves were fixed in a 
formalin-sucrose-acetic acid solution and 1 % 
formaldehyde-2.5 % glutaraldehyde in phos-
phate buffer, followed by preservation in neu-
tral buffered formalin. After these steps, all 
organs were embedded in paraffin and stained 
with hematoxylin and eosin for microscopy. 
Histopathological evaluation was conducted 
in fixed organs from the control and high-
dose groups and in tissues with gross lesions 
from all the groups. 
 
Statistical analysis 
Results were statistically analyzed using 
SAS software (version 9.3, SAS Institute Inc., 
U.S.A.). In the acute toxicity study, body 
weights were analyzed using a folded-F test. 
Two-tailed Student’s t-test was used on ho-
mogeneous data. In the subchronic toxicity 
study, body weight, food consumption, organ 
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weights, and hematology and clinical chemis-
try parameters were analyzed using Bartlett’s 
test. One-way analysis of variance (ANOVA) 
was used for homogeneous data and signifi-
cant values were examined using Dunnett’s 
test for multiple comparisons. Kruskal-Wallis 
test was used to analyze heterogeneous data, 
and significant results were examined using 
Steel’s test for multiple comparisons. Data 
obtained during and after the recovery period 
were analyzed for equality of variance using 
Student’s t-test. All differences were regarded 
as significant at p < 0.05 or p < 0.01. 
 
RESULTS 
In vitro functional profile of FM101 
FM101 was identified through structure 
based optimization of compounds. It was de-
termined that FM101 selectively binds to hu-
man A3AR with a Ki value of 1.44 nM (Jeong 
et al., 2008). We confirmed the functional ac-
tivity via the cAMP HTRF assay and β-arres-
tin translocation assays on the G protein or β-
arrestin dependent signals, respectively. 
FM101 inhibited forskolin-stimulated cAMP 
in CHO cells overexpressing human A3AR in 
a concentration-dependent manner (Figure 1). 
Potent agonism of FM101, as determined by 
cAMP inhibition through Gα protein-depend-
ent signaling, was observed, with an EC50 of 
104 nM. Translocation of β-arrestin was 
measured using a β-galactosidase comple-
mentation assay. The results indicated that 
FM101 was a potent antagonist of β-arrestin 
dependent signaling, with an IC50 of 44 nM 
(Figure 1). 
 
Acute oral dose toxicity study 
After a single dose of 2000 mg/kg FM101, 
all animals survived for 2 weeks until sched-
uled euthanasia. Stool that had the same hue 
as FM101 was observed 1 day after dosing in 
all the rats. Fecal volume in one male and 
three female rats was lower than other rats 1 
day after dosing. Abnormal clinical signs ob-
served on Day 1 returned to normal the day 
after dosing and did not reoccur afterward. 
 
 
Figure 1: Concentration-response curves of 
FM101 in cAMP and β-arrestin signaling path-
ways. (a) Agonist functions of FM101 as meas-
ured by the accumulation of cAMP. (b) Antagonist 
function of FM101 as measured by the transloca-
tion of β-arrestin. The results are expressed as 
mean ± standard error from independent experi-
ments. Data were from at least 3 separate exper-
iments providing similar results in duplicate. 
 
 
The mean body weights among the female 
rats on Days 1 and 3 after dosing (142.6 g and 
160.0 g, respectively) were significantly 
lower than the body weights in the control 
group (6.9 % and 3.8 % reduction, respec-
tively; p < 0.05). However, the body weight 
had recovered by Day 14 (Table 1). No 
grossly visible abnormalities were observed 
during the postmortem examination. 
 
Subchronic oral dose toxicity study 
Clinical signs  
No morbidity or mortality was observed 
in any dosing group during the treatment or 
recovery periods. Prone posture, decreased 
movement, and irregular respiration were ob-
served in several animals in all the treated  
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Table 1: Summary results of body weight during the acute toxicity study 
   
Unit: (g) 
Sex Group / Dose (mg/kg) 
Days after dosing 
0 1 3 7 14 
Male G1 Mean 159.4 183.3 205.6 250.8 312.4 
 0 S.D. 5.2 5.0 5.9 9.1 11.9 
  N 5 5 5 5 5 
 G2 Mean 160.1 173.6 197.3 239.1 303.9 
 2000 S.D. 5.2 8.6 11.3 10.0 6.4 
  N 5 5 5 5 5 
Female G1 Mean 133.2 153.1 166.4 188.4 212.5 
 0 S.D. 3.2 5.0 3.7 10.7 16.0 
  N 5 5 5 5 5 
 G2 Mean 132.0 142.6* 160.0* 182.4 207.7 
 2000 S.D. 4.8 7.1 4.3 5.6 13.4 
  N 5 5 5 5 5 
* indicates a significant difference from the controls according to the results of Student’s t-test (*p < 
0.05). S.D. indicates standard deviation and N indicates the number of animals. 
 
 
 
groups on Day 1. However, these signs disap-
peared prior to dosing on Day 2 or Day 3. Ear 
flushing was observed in several animals in 
all the groups on Days 2 and 3. In the 1000 
mg/kg/day dosing group, one male and one 
female rat exhibited soiled fur, scant feces, pi-
loerection, and/or irregular respiration during 
week 1; both animals recovered by Day 10. 
Yellowish-brown or loose stools were occa-
sionally observed in the 500 and 1000 
mg/kg/day groups during the treatment pe-
riod. Crust formation on the dorsocervical 
skin was observed during the last week of 
dosing in several animals in all the treatment 
groups, including the control; however this 
symptom disappeared during the recovery pe-
riod. 
Body weight and food consumption 
During the dosing period, there was no 
statistically significant difference in mean 
body weight among the control and treated 
groups (Figure 2). Individually, reduced body 
weight gain and reduced food consumption 
were observed in one male and one female an-
imal that received 1000 mg/kg/day during 
week 1 of dosing. Their weights were signifi-
cantly lower than the mean weight of the con-
trol group or other animals in the same group. 
When the body weights of these animals were 
compared between week 1 and the first day of 
dosing, the male animal gained 6 g (compared 
to a mean body weight gain of 61 g for the 
control group) and the female animal lost 42 
g. However, this reduction recovered during 
week 2 of dosing (Table 2). Therefore, these 
values were considered outliers and were not 
included in the calculation of average body 
weight or body weight gain in their respective 
groups. All other changes in body weight in 
the animals of the 1000 mg/kg/day group 
were not significant except for the body 
weight reduction observed in the two previ-
ously mentioned animals compared to the 
control group. 
Ophthalmology  
White dots or spots in the lens (anterior 
cortex or nucleus), opaque the cornea, and ret-
inal folds or zonal hyper-reflection in the 
fundi were sporadically observed in both the 
controls and the experimental groups during 
week 4 of dosing and week 2 of recovery. 
These observations were considered sponta-
neous or incidental as there was a lack of 
dose-dependency, and the rate of incidence 
did not differ significantly between the con-
trol and experimental groups.
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Figure 2: Mean body weight in (a) male and (b) 
female rats during the main experimental and re-
covery periods of the subchronic toxicity study. 
Hematology 
During week 4, the mean corpuscular vol-
ume and mean corpuscular hemoglobin in-
creased significantly in male rats receiving 
500 mg/kg/day (Table 3). The red blood cell 
count and prothrombin time decreased and 
absolute or relative neutrophil count in-
creased in the female rats in all the treatment 
groups. The absolute monocyte count signifi-
cantly increased in the female rats in the 1000 
mg/kg/day dosing group (p < 0.05). The he-
moglobin levels, basophil ratio, and number 
of monocytes increased in the female rats in 
the high-dose recovery group compared to the 
controls (p < 0.05). In males, only the baso-
phil ratio significantly increased (p < 0.01). 
However, these changes were within the nor-
mal variation and there were no relationships 
between sexes, which suggests that these 
changes were not FM101.
 
 
Table 2: Summary of body weights and body weight gain during the subchronic toxicity study 
   Unit: g
Group / Dose 
(mg/kg/day) 
Male  Female 
0 (control) 1000  0 (control) 1000 
Mean BW Mean BW* BW of M04# 
 Mean BW Mean BW* BW of F15# 
Week 0 223 222 216  174 171 179 
Week 1 283 274 222  198 192 137 
Week 2 341 330 267  220 216 224 
Week 3 386 371 289  241 235 241 
Week 4 415 398 311  252 248 256 
 
Mean BWG Mean BWG* BWG of M04# 
 Mean BWG Mean BWG* BWG of F15# 
Week 1 61 52 6  24 21 ‒42 
Week 2 58 55 45  21 24 87 
Week 3 45 41 22  21 19 17 
Week 4 29 27 22  11 13 15 
Body weight (BW) and body weight gain (BWG) were calculated based on the most recent individual 
body weight measurements. 
# M04 and F15 indicate the individual animal codes that showed reduced body weight. 
* Mean body weight at 1000 mg/kg/day with one outlier excluded for body weight reduction in each 
group (male and female).  
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Table 3: Summary of hematology and clinical pathology parameters in the subchronic toxicity study 
Parameters Main group (mg/kg/day) Recovery group (mg/kg/day) 
0 (control) 250 500 1000  0 (control) 1000  
Male rats 
   
RBC (106/μL) 8.07 ± 0.50 7.99 ± 0.33  7.92 ± 0.24  7.93 ± 0.42   8.46 ± 0.21 8.49 ± 0.47 
HGB (g/dL) 15.6 ± 0.8 15.7 ± 0.4 15.9 ± 0.4 15.6 ± 0.7 15.5 ± 0.5 15.9 ± 0.4 
MCV (fL) 56.8 ± 1.3 57.8 ± 0.7 59.2 ± 1.6# 57.5 ± 2.4 53.7 ± 2.4 54.5 ± 1.7 
MCH (pg) 19.4 ± 0.5 19.6 ± 0.3 20.1 ± 0.5** 19.7 ± 0.6 18.4 ± 0.5 18.8 ± 0.6 
MCHC (g/dL) 34.1 ± 0.3 34.0 ± 0.3 33.9 ± 0.5 34.4 ± 0.7 34.3 ± 0.7 34.4 ± 0.5 
Basophils (%) 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.1** 
PT (sec) 13.6 ± 1.2 12.7 ± 2.0 12.0 ± 2.0 11.9 ± 1.4 12.2 ± 1.2 12.8 ± 2.2 
TBil (mg/dL) 0.05 ± 0.01 0.05 ± 0.01  0.06 ± 0.01  0.06 ± 0.01*   0.07 ± 0.02 0.07 ± 0.02 
TCho (mg/dL) 50 ± 9 51 ± 10  46 ± 8  46 ± 8   49 ± 8 44 ± 5 
TG (mg/dL) 34 ± 7 28 ± 15  19 ± 8**  18 ± 10**   36 ± 14 25 ± 7 
TP (g/dL) 5.69 ± 0.25 5.83 ± 0.23  5.79 ± 0.14  5.70 ± 0.23   5.75 ± 0.21 5.81 ± 0.23 
Female rats 
RBC (106/μL) 8.00 ± 0.36 7.58 ± 0.25** 7.61 ± 0.33* 7.63 ± 0.23* 7.68 ± 0.35 7.99 ± 0.37 
HGB (g/dL) 15.5 ± 0.5 15.2 ± 0.5 15.0 ± 0.4 15.1 ± 0.4 14.6 ± 0.5 15.2 ± 0.5* 
MCH (pg) 19.4 ± 0.3 20.0 ± 0.5 19.7 ± 0.8 19.8 ± 0.6 19.0 ± 0.4 19.1 ± 0.7 
Neutrophils (103/μL) 0.76 ± 0.21 1.09 ± 0.30# 1.10 ± 0.34# 1.41 ± 0.57# 1.00 ± 0.40 1.30 ± 0.50 
Monocytes (103/μL) 0.18 ± 0.08 0.24 ± 0.05 0.24 ± 0.08 0.29 ± 0.09* 0.18 ± 0.07 0.27 ± 0.07*
Basophils (%) 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1* 
PT (sec) 9.5 ± 0.3 9.1 ± 0.2** 9.2 ± 0.2 9.1 ± 0.3** 9.2 ± 0.3 9.1 ± 0.2 
TBil (mg/dL) 0.07 ± 0.02 0.08 ± 0.01  0.09 ± 0.02  0.08 ± 0.02  0.07 ± 0.01 0.09 ± 0.02 
TCho (mg/dL) 50 ± 5 53 ± 10  62 ± 8**  60 ± 6*  55 ± 8 56 ± 13 
TG (mg/dL) 7 ± 2 7 ± 3  8 ± 3  6 ± 4  12 ± 2 10 ± 3 
TP (g/dL) 5.55 ± 0.28 5.94 ± 0.19**  5.90 ± 0.22**  6.01 ± 0.25**  6.00 ± 0.43 6.16 ± 0.26 
No. animals/sex 10 10  10   10   6 6 
RBC: red blood cell count, HGB: hemoglobin, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin 
concentration, PT: prothrombin time, TBil: total bilirubin, TCho: total cholesterol, TG: triglyceride, TP: total protein. 
Values indicate the mean ± standard deviation.  
Significantly different from control according to Steel test: # p < 0.05, ## p < 0.01. 
Significantly different from control according to Dunnett’s t-test in the main groups or Student’s t-test in the recovery groups: * p < 0.05, ** p < 0.01. 
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Clinical chemistry and urine analysis 
At week 4 after dosing, the level of tri-
glycerides in male rats was lower in the 500 
and 1000 mg/kg/day groups, whereas the total 
cholesterol levels in the females were signifi-
cantly higher in the 500 and 1000 mg/kg/day 
groups (Table 3). However, these changes 
were within normal variation and there was 
no relationship between sexes, which sug-
gests that these changes were not related to 
FM101. Total bilirubin levels were higher in 
the male animals in the 1000 mg/kg/day 
group. Furthermore, significant increases in 
total protein were observed in the female rats 
of all dosed groups. However, these signifi-
cant changes were slight and considered to be 
incidental, spontaneous, or within the range of 
historical data from the test facilities. Urine 
analyses during week 4 of dosing or week 2 
of recovery indicated occasional increases in 
protein, the presence of occult blood, and the 
presence of ketone bodies in the treated rats. 
These results were similarly considered to be 
incidental as the responses were noted in the 
historical data of Ina Research Inc. 
Organ weights 
At the end of the dosing and recovery pe-
riods, several parameters were significantly 
different compared to the control group (Ta-
ble 4). For instance, in the 1000 mg/kg/day 
group, absolute heart weights were lower in 
males, whereas the relative heart weights 
were higher in females. Relative liver weights 
were higher in females receiving 250 
mg/kg/day, whereas the absolute and relative 
liver weights were lower in males receiving 
1000 mg/kg/day. In the recovery groups, the 
absolute and relative weights of the thymus as 
well as relative weights of the lungs, kidneys, 
and testis were greater in male rats receiving 
1000 mg/kg/day compared to the control 
group. 
Although the above differences were sig-
nificant, they were considered incidental or 
spontaneous because they were within the 
range of historical data from the test facility 
and there was a lack of supportive findings in 
clinical pathology, histopathology, and other 
examinations. 
Gross findings and histopathology 
Dorsocervical skin crusts could still be 
observed in one or two rats per group at doses 
of 250 or 1000 mg/kg/day at the time of nec-
ropsy after 4 weeks’ dosing. In one male rat 
in the control group, a nodule on the spleen 
was observed. Among the recovery group an-
imals, a dark reddish focus on the mucosal 
layer in the glandular stomach was observed 
in one female rat in the 1000 mg/kg/day dose 
group. According to the histopathological 
evaluation, inflammatory cell infiltration 
and/or pustules found in the dermis or subcu-
tis were related to the crust formation that was 
macroscopically observed (Table 5). Further-
more, the focal lymphoid hyperplasia found 
on the spleen corresponded with the macro-
scopically observed nodule in the control 
group. Other findings were not considered 
test substance-related because their incidence 
rates did not significantly differ from those of 
the control group. Further, they lacked dose-
dependency, had a low degree of differences 
between the control and high dose groups, or 
had other indications of spontaneity. 
 
DISCUSSION 
Our findings demonstrate that FM101 is a 
biased modulator of A3AR with functional ag-
onism toward G protein activity and antago-
nism toward β-arrestin recruitment. These re-
sults also suggest that FM101 is safe and well-
tolerated upon single and multiple dosing in 
rats. Based on the results of the safety assess-
ment in this study, a Phase I clinical trial of 
FM101 administered orally to healthy volun-
teers has been initiated (Lee et al., 2018). 
As a member of the GPCR family, A3AR 
is highly expressed on the cell membrane. 
Adenosine, which is released in the extracel-
lular space, binds to adenosine receptors on 
the target cell surface and causes the dissoci-
ation of the G-protein subunits Gα, Gβ, and Gγ 
(Chen et al., 2013). The G protein regulates 
the activities of secondary messengers and 
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Table 4: Summary of absolute and relative organ weights in the subchronic toxicity study 
Organs Main group (mg/kg/day) Recovery group (mg/kg/day)
0 (control) 250 500 1000 0 (control) 1000 
Male rats 
    
Thymus  (mg) 592 ± 116 581 ± 128 584 ± 102 479 ± 107 387 ± 53 527 ± 118* 
% of body weight 151.1 ± 25.8 149.5 ± 30.7 150.7 ± 21.6 132.0 ± 20.1 88.3 ± 12.7 126.7 ± 26.7** 
Lung  (g) 1.42 ± 0.15 1.45 ± 0.03 1.45 ± 0.09 1.38 ± 0.13 1.45 ± 0.13 1.51 ± 0.08 
% of body weight 0.363 ± 0.024 0.374 ± 0.014 0.375 ± 0.019 0.385 ± 0.039 0.329 ± 0.016 0.365 ± 0.020** 
Heart  (g) 1.425 ± 0.226 1.411 ± 0.143 1.305 ± 0.083 1.215 ± 0.112# 1.493 ± 0.166 1.445 ± 0.145 
% of body weight 0.365 ± 0.054 0.364 ± 0.031 0.339 ± 0.026 0.338 ± 0.014 0.339 ± 0.030 0.349 ± 0.042 
Liver  (g) 11.9 ± 1.5 11.6 ± 0.8 11.1 ± 0.9 10.0 ± 1.5** 12.5 ± 2.4 11.6 ± 0.7 
% of body weight 3.031 ± 0.177 2.984 ± 0.157 2.878 ± 0.107 2.771 ± 0.154** 2.805 ± 0.248 2.800 ± 0.110 
Kidney  (g) 3.08 ± 0.31 3.07 ± 0.16 3.05 ± 0.23 2.85 ± 0.32 3.11 ± 0.56 3.33 ± 0.25 
% of body weight 0.788 ± 0.043 0.793 ± 0.041 0.790 ± 0.040 0.793 ± 0.044 0.702 ± 0.062 0.803 ± 0.042** 
Testis  (g) 3.34 ± 0.21 3.16 ± 0.29 3.29 ± 0.25 3.25 ± 0.31 3.37 ± 0.37 3.64 ± 0.26 
% of body weight 0.859 ± 0.075 0.819 ± 0.100 0.854 ± 0.066 0.918 ± 0.189 0.767 ± 0.067 0.876 ± 0.018** 
Female rats 
Thymus  (mg) 459 ± 63 501 ± 157 487 ± 79 377 ± 72 352 ± 69 416 ± 93 
% of body weight 193.9 ± 26.5 213.5 ± 53.3 210.4 ± 35.9 166.6 ± 31.3 142.3 ± 29.9 159.0 ± 27.3 
Lung  (g) 1.12 ± 0.06 1.12 ± 0.08 1.14 ± 0.10 1.13 ± 0.09 1.11 ± 0.09 1.20 ± 0.07 
% of body weight 0.472 ± 0.030 0.484 ± 0.032 0.489 ± 0.017 0.500 ± 0.037 0.448 ± 0.010 0.462 ± 0.020 
Heart  (g) 0.861 ± 0.107 0.886 ± 0.048 0.894 ± 0.068 0.926 ± 0.082 0.899 ± 0.087 0.908 ± 0.093 
% of body weight 0.363 ± 0.036 0.383 ± 0.030 0.386 ± 0.030 0.410 ± 0.036** 0.362 ± 0.024 0.350 ± 0.028 
Liver  (g) 6.7 ± 0.7 7.0 ± 0.6 6.9 ± 0.6 6.7 ± 0.6 7.0 ± 0.5 7.3 ± 0.6 
% of body weight 2.811 ± 0.196 3.024 ± 0.145* 2.952 ± 0.134 2.968 ± 0.161 2.811 ± 0.127 2.813 ± 0.157 
Kidney  (g) 1.87 ± 0.24 1.86 ± 0.13 1.86 ± 0.11 1.78 ± 0.11 1.80 ± 0.11 1.99 ± 0.23 
% of body weight 0.788 ± 0.074 0.804 ± 0.055 0.806 ± 0.055 0.787 ± 0.056 0.725 ± 0.036 0.765 ± 0.075 
No. animals/sex 10 10 10 10  6  6  
Values indicate the mean ± standard deviation.  
Significantly different from control according to Steel test: # p < 0.05, ## p < 0.01. 
Significantly different from control according to Dunnett’s t-test in the main groups or Student’s t-test in the recovery groups: * p < 0.05, ** p < 0.01. 
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Table 5: Incidence and severity of microscopic findings in the subchronic toxicity study 
Sex 
 
Male
 
Female
Organs Dose 
 
Main group Recovery group 
  
Main group Recovery group 
 
 
(mg/kg/day) 
 
0 250 1000  0 1000  
  
0 250 1000  0 1000  
 
Eye 
      
 
Retina dysplasia 
      
 
present 
 
1 - 2 1 0 
  
0 - 1 0 0 
 
 
Corneal mineralization 
   
minimal 0 - 0 1 0 0 - 0 0 0 
Liver 
    
 
Fatty change, hepatocyte, periportal 
   
 
minimal 
 
0 - 0 0 0 
  
1 - 0 1 0 
 
 
Microgranuloma 
    
 
minimal 
 
8 - 5 5 5 
  
8 - 5 6 5 
 
 
mild 
 
0 - 0 1 1 
  
0 - 0 0 1 
 
Focal necrosis 
mild 0 - 0 1 0 0 - 0 0 0 
Kidney 
Mononuclear cell infiltrate 
minimal 1 - 4 1 0 0 - 1 0 0 
Cyst 
present 1 - 2 1 0 0 - 0 0 0 
Stomach 
Mononuclear cell infiltrate, focal submucosa 
mild 0 - 1 0 0 0 - 0 0 0 
Focal erosion/ulcer 
mild 0 - 0 0 0 0 - 0 0 1 
Skin 
Inflammatory cell infiltrate, dermis/subcutis 
mild 0 1 1 0 0 0 0 0 0 0 
 Pustule 
 minimal 0 0 0 0 0 0 1 0 0 0 
 mild 
 
0 2 1 0 0 
  
0 1 1 0 0 
 
Spleen 
     
 Extramedullary hematopoiesis 
   
 minimal 
 
5 - 4 5 5 
  
1 - 2 5 5 
 
 mild 
 
0 - 1 0 0 
  
0 - 1 1 0 
 
 Hyperplasia, lymphoid, focal 
   
 mild 1 - 0 0 0 0 - 0 0 0 
- indicates not examined 
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plays an important role in transferring extra-
cellular signals to the cytosol. The intracellu-
lar signaling pathways activated by GPCRs, 
including A3AR are regulated by β-arrestin as 
well as the G protein subunits (Reiter et al., 
2012). As a result, the concept of the func-
tional selectivity of GPCR has been estab-
lished; this concept suggests that, depending 
on their signaling pathway, different ligands 
of GPCR exert different efficacies or safety 
profiles when binding to the same target re-
ceptor (Urban et al., 2007; Tan et al., 2018). 
FM101 has been functionally characterized 
by its ability to affect the G protein and β-ar-
restin pathways. It displays biased functional 
activity: its G protein agonism inhibits the ac-
cumulation of cAMP (EC50 = 104 nM, Emax = 
82 %) and prevents the recruitment of β-arres-
tin (IC50 = 44 nM, Emax = 81 %). A3AR antag-
onists against cAMP signaling and partial ag-
onists for β-arrestin recruitment have been 
identified as functionally biased ligands at the 
A3AR (Gao and Jacobson, 2008). However, a 
functionally biased ligand that is an A3AR ag-
onist with regard to cAMP-dependent signal-
ing and an antagonist for β-arrestin-dependent 
signaling has not yet been reported. There-
fore, this study provides, to our knowledge, 
the first safety profile possibility for a biased 
agonist of A3AR. 
The amino acid sequence of A3AR 
demonstrates substantial variation among 
mammalian species (Alnouri et al., 2015); for 
instance, there is only approximately 71–
74 % sequence homology between humans 
and rodents (Klotz, 2010) and about 90 % ho-
mology between rats and mice (Alnouri et al., 
2015). Due to these species-dependent differ-
ences, many potential A3AR agonists/antago-
nists have shown lower potency or activity in 
rodents despite being highly potent in humans 
(Alnouri et al., 2015; Klotz, 2010). Therefore, 
rodent models may not be suitable for such 
studies. In this study, FM101 was found to be 
a species-independent and selective ligand for 
both human and rodent A3AR subtypes. This 
allows us to use rodents as a model for the 
evaluation of the toxicological profile of 
FM101. 
In a previous experiment to develop new 
chemical entities targeting A3AR, a full A3AR 
agonist was found to be safe and well-toler-
ated in humans and animals. CF101, a selec-
tive A3AR full agonist that is currently under 
development for rheumatoid arthritis and pso-
riasis (Fishman and Cohen, 2016), was well-
tolerated in nonclinical studies and Phase I 
clinical trials with healthy subjects (van 
Troostenburg et al., 2004). CF101-related 
clinical observations were made after a single 
dose of 10 mg in healthy volunteers with 
symptoms of flushing, tachycardia, nausea, 
and vomiting observed. Headache, drowsi-
ness, flushes, and dizziness were also ob-
served among healthy volunteers receiving 
multiple doses of 5 mg. These observations 
diminished over time in these studies. 
In our acute toxicity study, FM101 was 
well-tolerated, suggests that the approximate 
lethal dose of FM101 is likely much higher 
than 2000 mg/kg. Furthermore, over the 4 
weeks dosing period during the subchronic 
toxicity study, clinical signs included flush-
ing, irregular respiration, or prone posture. 
However, these symptoms diminished over 
time within a week, which was similar to the 
observations with CF101, despite the much 
higher dose levels. As such, while these signs 
are considered test substance-related, they are 
not toxicologically significant. Moreover, 
these signs disappeared within a week during 
the early stages of the dosing period and did 
not affect general health or cause changes in 
clinical pathology or histopathology in the 
250 or 500 mg/kg/day groups. Although 
changes in fecal characteristics were observed 
in the 500 and 1000 mg/kg groups, these find-
ings also lack toxicological significance as 
they were only observed during the first two 
weeks of dosing and did not affect the diges-
tive system according to pathological or his-
topathological findings. Overall, FM101 
showed similar clinical outcomes with a po-
tentially superior safety margin compared to 
the full agonists, as these signs were observed 
only occasionally or for a short duration. At 
1000 mg/kg/day, we observed deteriorated 
physical conditions, decreased body weight, 
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and reduced food consumption during week 1 
in one female rat. We also observed slower 
weight gain and decreased food consumption 
in one male rat. No changes suggestive of de-
teriorating physical condition were noted fol-
lowing clinical or histopathological examina-
tion. These findings were considered to be the 
effects of treatment with the test article, but 
were limited to only two animals, both of 
which recovered within 2 weeks of the dosing 
period. As such, we do not consider these 
findings to be toxicologically significant. Ad-
ditionally, we will evaluate and assess the cor-
relation of these signs with toxicological sig-
nificance in future multiple-dosing studies 
over long term. 
A3AR is densely distributed in the human 
lung and liver, but less so in other tissues 
(Salvatore et al., 1993). In rats, it is highly ex-
pressed in the testes (Zhou et al., 1992). We 
evaluated the effects of FM101 on all of these 
organs. We observed a significant increase in 
the liver weight among females receiving 250 
mg/kg/day and lower absolute and relative 
liver weights among males receiving 1000 
mg/kg/day at the termination of the dosing pe-
riod. As with previous findings, these changes 
are considered incidental due to a lack of 
dose-dependency or supporting changes in 
clinical pathology or histopathology. Addi-
tionally, no test article-related findings were 
observed in the testes or lungs. According to 
the ophthalmological evaluation, white dots 
or spots in the lens, opacity of the cornea and 
retinal folds, or zonal hyper-reflection in the 
fundi were sporadically observed in the 
FM101-treated groups during week 4 of dos-
ing or week 2 of recovery. These lesions were 
also considered incidental due to a lack of 
dose-dependency. 
In conclusion, FM101, an A3AR modula-
tor, has been identified as a biased ligand that 
acts as a G protein agonist and β-arrestin an-
tagonist. In this study, we demonstrated the 
toxicological potential of FM101 in rodents. 
The compound did not induce significant 
toxic changes, and we believe that the approx-
imate lethal dose in rats is likely greater than 
the maximum dose of 2000 mg/kg tested in 
this study. Chronic exposure of up to 1000 
mg/kg/day over 28 days indicates a no ob-
served adverse effect level (NOAEL) of 1000 
mg/kg/day for male and female rats. These 
findings support the further investigation of 
FM101 in clinical trials. However, we did not 
evaluate the toxicological profile of FM101 in 
non-rodent animals or humans, and differ-
ences between its effects and could only be 
determined using in vitro assessments. Fur-
ther studies should address these concerns. 
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